Acute myeloid leukemia (AML) cells possess different mechanisms to escape immune recognition. Type-I interferon (IFN) is primarily involved in combating viral infections. However, emerging preclinical and clinical evidence suggests that type-I IFN production within...
The c-MYB (MYB) oncogenic transcription factor is a key regulator of hematopoietic cell differentiation and proliferation. Recurrent genetic lesions or dysregulation of MYB have been identified in a variety of cancers, including adenoid cystic carcinoma (ACC), acute...
Post-MyeloProliferative Neoplasm Acute Myeloid Leukemia (Post-MPN AML) is an aggressive and lethal hematologic malignancy arising from myeloproliferative neoplasms. Currently, there is no standard of care treatment for post-MPN AML patients, with allogeneic stem cell...
Introduction: Studies have previously reported improved outcomes for patients with acute myeloid leukemia (AML) in academic over nonacademic settings potentially due to the availability of multidisciplinary teams, clinical trials and increased resources (median...
INTRODUCTIONTo attempt inducing a complete remission (CR) prior to allogeneic hematopoietic cell transplantation (alloHCT) in patients with active AML after first induction or untreated first relapse is considered as standard of care. This standard, however, has never...
Background Acute myeloid Leukemia (AML) is a heterogenous disease that exhibits a dynamic mutational landscape. Patients with relapsed/refractory (R/R) AML who have failed standard therapies, including venetoclax (VEN), hypomethylating agents (HMA), and/or FLT3...
Recent Comments